EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors

Agustina Oller iD, Patrick Kemmeren iD, Daniela Perotti iD, Harm van Tinteren iD, Arnauld Verschuur iD, Filippo Spreafico iD, Jesper Brok, Rhoikos C J Furtwängler iD, Tanzina Chowdhury, Reem Al-Saadi, Gordan M Vujanic iD, Amy L Treece und 9 weitere

JCO Precision Oncology · 2026-05 · 10 (5)

DOI: 10.1200/po-25-01017 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Agustina Oller und 20 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Wilms Tumor, Biomarkers, Tumor, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Molecular biomarkers are increasingly used for risk stratification, particularly in up-front surgery settings (Children's Oncology Group trials), whereas in preoperative chemotherapy setting, the ongoing International Society of Pediatric Oncology (SIOP)-Renal Tumor Study Group-2016 UMBRELLA study aims to validate selected biomarkers for future risk-adapted treatment strategies. This systematic review summarizes all literature on the prognostic value of these biomarkers. MATERIALS AND METHODS A systematic literature review (PubMed and Embase; up to January 2025) included studies with ≥50 de novo Wilms tumors (WTs). Eligible biomarkers included copy number variations; 1q gain, 1p and/or 16q loss of heterozygosity (LOH)/loss, 12 gain, 14q loss, 22 loss, 11p15 LOH/loss of imprinting (LOI), and structural somatic variants ( TP53 [and/or 17p loss], MYCN , FBXW7 , WT1 , WTX , SIX1/SIX2 , DROSHA , DGCR8 , AMER1 , CTNNB1 , GPC3 , MLLT1 , DICER1 , DIS3L2 ). Outcome included relapse-free survival, event-free survival (EFS), and overall survival (OS). Risk of bias was assessed with quality in prognosis studies tool. RESULTS Low-bias multivariable/stratified analyses identified 1q gain as worse EFS and 1p and/or 16q LOH/loss as worse EFS/OS prognostic factors, in up-front nephrectomy settings. Preoperative chemotherapy settings revealed similar trends with lacking significance. TP53 and MYCN were adverse prognostic in univariate analyses. No prognostic data were available for the remaining variants. CONCLUSION 1q gain and 1p and/or 16q LOH/loss emerge as independent prognostic biomarkers in up-front nephrectomy settings. Evidence remains limited in preoperative chemotherapy settings, particularly when using SIOP-oriented treatment algorithms. Prognostic value of TP53 , MYCN , and 11p15 LOH/LOI warrants further validation in both settings. This highlights the need for adequately powered prospective studies, specifically in the preoperative chemotherapy setting, to establish reliable molecular biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorBiomarkers, TumorKidney NeoplasmsHumansPrognosisLoss of Heterozygosity

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Center for Molecular Medicine, UMC Utrecht and Utrecht University, Utrecht, the Netherlands.
  • Predictive Medicine: Molecular Bases of Genetic Risk, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Department of Pediatric Haematology-Oncology, La Timone Children's Hospital, AP-HM, Marseille, France.
  • Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

ORCID-Profile: Agustina Oller, Patrick Kemmeren, Daniela Perotti, Harm van Tinteren, Arnauld Verschuur, Filippo Spreafico, Rhoikos C J Furtwängler, Gordan M Vujanic, Jarno Drost, Martine van Grotel, Elizabeth A Mullen, Nicholas F Evageliou, Norbert Graf, Andrew L Hong, Manfred Gessler, James I Geller, Marry M van den Heuvel-Eibrink

Zitieren

APA

Oller, A., Kemmeren, P., Perotti, D., van Tinteren, H., Verschuur, A., Spreafico, F., Brok, J., Furtwängler, R. C. J., Chowdhury, T., Al-Saadi, R., Vujanic, G. M., Treece, A. L., Drost, J., van Grotel, M., Mullen, E. A., Evageliou, N. F., Graf, N., Hong, A. L., Gessler, M., …, & van den Heuvel-Eibrink, M. M. (2026). Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-25-01017

Vancouver

Oller A, Kemmeren P, Perotti D, van Tinteren H, Verschuur A, Spreafico F, et al. Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-25-01017

BibTeX
@article{Oller2026,
  author = {Oller, Agustina and Kemmeren, Patrick and Perotti, Daniela and van Tinteren, Harm and Verschuur, Arnauld and Spreafico, Filippo and Brok, Jesper and Furtwängler, Rhoikos C J and Chowdhury, Tanzina and Al-Saadi, Reem and Vujanic, Gordan M and Treece, Amy L and Drost, Jarno and van Grotel, Martine and Mullen, Elizabeth A and Evageliou, Nicholas F and Graf, Norbert and Hong, Andrew L and Gessler, Manfred and Geller, James I and van den Heuvel-Eibrink, Marry M},
  title = {Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1200/po-25-01017}
}
Kostenlos starten →